文献速递慢性肾脏病肾小球疾病

斯坦尼钙蛋白-1:糖尿病肾病与心血管疾病的新型介质

Stanniocalcin-1: A Novel Mediator in Diabetic Kidney Disease and Cardiovascular Disease.
PubMed 文献 · Kidney Int Rep · 2024-11-09

综述探讨斯坦尼钙蛋白-1(STC-1)的分子生物学与生理功能,及其在糖尿病肾病和心血管疾病中的作用。STC-1在人类中调节钙磷稳态,具有抗氧化、抗炎、抗凋亡活性,在糖尿病肾病中发挥肾脏保护作用,并在缺血再灌注中显示心脏保护特性。

要点

  • STC-1在健康人血中通常不存在,但在妊娠、癌症和CKD等情况下可检测到。
  • STC-1具有抗氧化、抗炎和抗凋亡活性,在糖尿病肾病中发挥肾脏保护作用。
  • STC-1在缺血再灌注中具有心脏保护特性,可能为糖尿病肾病相关心血管疾病提供新治疗策略。

核心结论

  • STC-1是一种在糖尿病肾病和心血管疾病中具有潜在保护作用的新型介质。

研究设计与样本

  • 综述,检索范围未明确报告。

主要发现

  • STC-1在健康人血中通常不存在,但在妊娠、癌症和CKD等情况下可检测到。
  • STC-1具有抗氧化、抗炎和抗凋亡活性,在糖尿病肾病中发挥肾脏保护作用。
  • STC-1在缺血再灌注中具有心脏保护特性。

临床怎么用

  • STC-1可能为糖尿病肾病相关心血管疾病的治疗提供新策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diabetes mellitus represents a group of metabolic diseases characterized by hyperglycemia from defects in insulin secretion, action, or both. The prevalence of type 2 diabetes mellitus, characterized by insulin resistance, has increased over time in the UK, and is the most prevalent cause of chronic kidney disease (CKD). Cardiovascular complications are a major cause of mortality for these patients. Stanniocalcin (STC), originally identified in bony fish as a hormone regulating calcium levels, has since been found in mammals, including humans. In fish, STC functions as an antihypercalcemic factor. Mammals possess 2 STC orthologues, STC-1 and STC-2, with STC-1 demonstrating significant sequence and functional conservation across species. Unlike fish, STC-1 is not normally present in the blood of healthy humans. However, it can be detected in certain conditions such as pregnancy, cancer, and CKD. In humans, STC-1 has diverse roles, including modulation of calcium and phosphate homeostasis, and it is implicated in kidney and cardiovascular protection. It has been reported that STC-1 has antioxidant, anti-inflammatory, and antiapoptotic activities, playing a role in renoprotection in diabetic nephropathy. This review explores the molecular biology of STC-1, its physiological functions, and its emerging role in GKDs, particularly diabetic and cardiovascular diseases. We highlight its potential protective mechanisms against hypercalcemia, its antioxidant and anti-inflammatory properties, and its cardioprotective properties in ischemia-reperfusion. Further research into STC-1 could provide new insights into therapeutic strategies for managing diseases characterized by calcium imbalance and lead to new treatments for the cardiovascular morbidity associated with diabetic kidney disease.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Mookerjee S, Whitley G, Banerjee D, et al. Stanniocalcin-1: A Novel Mediator in Diabetic Kidney Disease and Cardiovascular Disease. Kidney Int Rep. 2024. PMID: 39990897. doi:10.1016/j.ekir.2024.10.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。